undamentalytics Newsletter
Sign in

Foghorn Therapeutics Inc. income statement

In fiscal 2025, Foghorn Therapeutics Inc. reported revenue of $30.9m, up 36.8% on the year before, operating income of −$86.4m (a -279.5% margin) and net income of −$74.3m, or −$1.18 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue011934233137
Research and development5880106110958579
General and administrative11223132282826
Operating income−69−101−117−108−103−86−73
Interest expense12—————
Income before tax——−109−94−87——
Income tax0—0400—
Net income−69−101−109−98−87−74−65
Diluted EPS−$6.23−$2.73−$2.62−$2.34−$1.58−$1.18−$0.97
Diluted shares (average)11m37m42m42m55m63m67m
EBITDA−67−98−114−104−100−83−71

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FHTX vs NBTXFHTX vs ZYMECUE vs FHTXCCCC vs FHTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Foghorn Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Foghorn Therapeutics Inc.